|
|
|
| NEW
PRODUCTS
 |
| The Right Choice For Nausea
and Vomiting |
 |
Composition :
| Each tablet contains
domperidone maleate 12.73 mg equivalent to domperidone
10 mg.
|
Action:
| Pharmacology:
Domperidone is a dopamine antagonist with antiemetic
activity. The drug does not cross the blood-brain
barrier. When administered to adults, extrapyramidal
side effects are rarely observed. However, domperidone
can stimulate release of prolactin by the pituitary
gland. The antiemetic activity may be the combined
result of its peripheral (gastrokinetic) effect
and its antagonistic action against dopamine reseptors
in the chemoreceptor trigger zone located outside
the blood-brain barrier in the postrema area. |
Indication :
 |
Adults:
Treatment of nausea and vomiting from various origin
in adults. Prophylactic use in post-surgery vomiting
is not recommended. Treatment of nausea and vomiting
induced by L-dopa and bromocriptine. Symptomatic
treatment of functional dyspepsia. Chronic administration
of domperidone is discouraged. |
|
Children:
Pediatric use is not recommended, except when indicated
to prevent nausea and vomiting associated with cancer
chemotherapy or radiotherapy. |
Dosage & Administration:
Dosage
and frequency of administration depend on the
severity and duration of symptoms.
Treatment of Nausea and Vomiting:
Adults (Including the Elderly):
10-20 mg with an interval of 4-8 hours. Children:
0.2-0.4 mg/kg with an interval of 4-8 hours.
Symptomatic Treatment of Functional Dyspepsia:
Adults (Including the Elderly):
10-20 mg, 3 times daily, and once at bedtime (10-20
mg) depending on clinical response. Duration of
treatment should not exceed 12 weeks.
Children: DOM®
is not recommended.
|
Contraindications:
Patients with known
hypersensitivity to Domperidone.
Domperidone should not be used if gastric motility
attack is endangering the patients eg, hemorrhage,
mechanical obstruction or gastrointestinal perforation.
Patients with prolactinoma, a pituitary gland tumor
secreting prolactin. Children (except for the preventionof
nausea and vomiting due to chemotherapy and radiotherapy
of cancer). Pregnant women. |
Precautions:
| Long-term therapy is
discouraged. Use with caution in lactating mothers
and patients with hepatic and renal dysfunctions. |
Adverse Reactions:
| Domperidone can induce
hyperprolactinemia. Extrapyramidal effects seldom
occur because the drug does not pass the blood-brain
barrier. Occasionally, hyperprolactinemia can lead
to neuro-endocrinological phenomena eg, galactorrhea
and gynecomastia. Allergic reactions seldom occur. |
Interactions:
Opioid analgesics and/or
antimuscarinic agents antagonize the antidyspepsia
effects of domperidone. Domperidone, having a gastrokinetic
effect, may influence the absorption of oral drugs
administered concomitantly, especially drugs having
an enteric-coated or delayed formulation. The simultaneous
administration of anticholinergic agents may antagonize
the antidyspepsia effect of domperidone. Antiacids
and antisecretic agents should not be administered
concomitantly, because these drugs may lower the
bioavailability of domperidone.
Concomitant administration is possible with neurologic
agents, which exert no potentiation; dopamine antagonists
(bromocriptine, L-dopa) where undesirable peripheral
effects eg, digestive disorders, nausea and vomiting
can be suppressed without preventing the central
action. |
Presentation:
| Tab 10
mg (film-coated) x 3 x 10’s. Susp 5 mg/5 mL
x 60 mL. |
|
|
|
|
